In 2004, NIAID established the Atopic Dermatitis and Vaccinia Network (ADVN) to better understand why some people with atopic dermatitis are at high risk for eczema vaccinatum, a rare and severe adverse reaction to the smallpox vaccine.
In 2010, NIAID expanded the goals of the ADVN and renamed it the Atopic Dermatitis Research Network (ADRN). ADRN scientists aim to understand host defense mechanisms and immune system responses in the skin by comparing responses to viral and bacterial skin infections in healthy individuals with those in people with atopic dermatitis. Ongoing clinical and animal research examines
Learn more about the ADRN.
Last Updated May 15, 2013